Phosphatonins and the regulation of phosphate homeostasis

Annual Review of Physiology

Volumn 69, Issue , 2007, Pages 341-359

  Berndt, Theresa ^a   Kumar, Rajiv ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

1 ,25 dihydroxyvitamin D; Fibroblast growth factor 23; Fibroblast growth factor 7; Matrix extracellular phosphoglycoprotein; Parathyroid hormone; Phosphatonins; Secreted frizzled related protein 4; Sodium phosphate cotransporters

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIDIOL 1 MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 23; FRIZZLED PROTEIN; KERATINOCYTE GROWTH FACTOR; PARATHYROID HORMONE; PHOSPHATE; SECRETED FRIZZLED RELATED PROTEIN 4; SODIUM PHOSPHATE COTRANSPORTER; UNCLASSIFIED DRUG;

BONE MINERALIZATION; ENERGY METABOLISM; ENZYME ACTIVITY; HUMAN; HYPOPHOSPHATEMIA; METABOLIC REGULATION; NONHUMAN; NUCLEIC ACID SYNTHESIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HOMEOSTASIS; HUMANS; PHOSPHATE TRANSPORT PROTEINS; PHOSPHATES; PHOSPHORUS;

EID: 33947365189     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.69.040705.141729     Document Type: Review

References (105)

1. Cohen P. 1989. The structure and regulation of protein phosphatases. Annu. Rev. Biochem. 58:453-508
2. Hubbard SR, Till JH. 2000. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:373-98
3. Hunter T, Cooper JA. 1985. Protein-tyrosine kinases. Annu. Rev. Biochem. 54:897-930
4. Krebs EG, Beavo JA. 1979. Phosphorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 48:923-59
5. Neuman W. 1980. Bone material and calcification mechanisms. In Fundamental and Clinical Bone Physiology, ed. M Urist, pp. 83-107. Philadelphia: J.B. Lippincott Co.
6. Haramati A, Mulroney SE, Webster SK. 1988. Developmental changes in the tubular capacity for phosphate reabsorption in the rat. Am. J. Physiol. 255:F287-91
7. Mulroney SE, Lumpkin MD, Haramati A. 1989. Antagonist to GH-releasing factor inhibits growth and renal Pi reabsorption in immature rats. Am. J. Physiol. 257:F29-34
8. Knochel JP. 1977. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch. Intern. Med. 137:203-20
9. Knochel JP, Barcenas C, Cotton JR, Fuller TJ, Haller R, Carter NW. 1978. Hypophosphatemia and rhabdomyolysis. Trans. Assoc. Am. Physiol. 91:156-68
10. Slatopolsky E. 2003. New developments in hyperphosphatemia management. J. Am. Soc. Nephrol. 14:5297-99
11. Slatopolsky E, Bricker NS. 1973. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int. 4:141-45
12. Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS. 1972. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int. 2:147-51
13. Slatopolsky E, Gradowska L, Kashemsant C, Keltner R, Manley C, Bricker NS. 1966. The control of phosphate excretion in uremia. J. Clin. Invest. 45:672-77
14. Slatopolsky E, Robson AM, Elkan I, Bricker NS. 1968. Control of phosphate excretion in uremic man. J. Clin. Invest. 47:1865-74
15. Werner A, Kinne RK. 2001. Evolution of the Na-P(i) cotransport systems. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280:R301-12
16. Murer H. 1992. Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions. J. Am. Soc. Nephrol. 2:1649-65
17. Murer H, Biber J. 1996. Molecular mechanisms of renal apical Na/phosphate cotransport. Annu. Rev. Physiol. 58:607-18
18. Murer H, Hernando N, Forster I, Biber J. 2000. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol. Rev. 80:1373-409
19. Murer H, Hernando N, Forster I, Biber J. 2003. Regulation of Na/Pi transporter in the proximal tubule. Annu. Rev. Physiol. 65:531-42
20. Hernando N, Biber J, Forster I, Murer H. 2005. Recent advances in renal phosphate transport. Ther. Apher. Dial. 9:323-27
21. Madjdpour C, Bacic D, Kaissling B, Murer H, Biber J. 2004. Segment-specific expression of sodium-phosphate cotransporters NaPi-IIa and -IIc and interacting proteins in mouse renal proximal tubules. Pflügers Arch. 448:402-10
22. Ohkido I, Segawa H, Yanagida R, Nakamura M, Miyamoto K. 2003. Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney. Pflügers Arch. 446:106-15
23. Tanaka Y, Deluca HF. 1974. Role of 1,25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proc. Natl. Acad. Sci. USA 71:1040-44
24. Tanaka Y, Frank H, DeLuca HF. 1972. Role of 1,25-dihydroxycholecalciferol in calcification of bone and maintenance of serum calcium concentration in the rat. J. Nutr. 102:1569-77
25. Tanaka Y, Frank H, DeLuca HF. 1973. Biological activity of 1,25-dihydroxyvitamin D3 in the rat. Endocrinology 92:417-22
26. Tanaka Y, Frank H, DeLuca HF. 1973. Intestinal calcium transport: stimulation by low phosphorus diets. Science 181:564-66
27. Tanaka Y, Deluca HF. 1973. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch. Biochem. Biophys. 154:566-74
28. i content in vitamin D receptor null mice. Am. J. Physiol. Renal Physiol. 287:F39-47
29. Berndt T, Knox F. 1992. Renal regulation of phosphate excretion. In The Kidney: Physiology and Pathophysiology, ed. D Seldin, G Giebisch, pp. 2511-32. New York: Raven Press
30. Berndt TJ, Schiavi S, Kumar R. 2005. "Phosphatonins" and the regulation of phosphorus homeostasis. Am. J. Physiol. Renal Physiol. 289:F1170-82
31. Chase LR, Aurbach GD. 1967. Parathyroid function and the renal excretion of 3′5′-adenylic acid. Proc. Natl. Acad. Sci. USA 58:518-25
32. Aurbach GD, Heath DA. 1974. Parathyroid hormone and calcitonin regulation of renal function. Kidney Int. 6:331-45
33. Aurbach GD, Keutmann HT, Niall HD, Tregear GW, O'Riordan JL, et al. 1972. Structure, synthesis, and mechanism of action of parathyroid hormone. Recent Prog. Horm. Res. 28:353-98
34. Condamine L, Menaa C, Vrtovsnik F, Friedlander G, Garabedian M. 1994. Local action of phosphate depletion and insulin-like growth factor 1 on in vitro production of 1,25-dihydroxyvitamin D by cultured mammalian kidney cells. J. Clin. Invest. 94:1673-79
35. Martin DR, Ritter CS, Slatopolsky E, Brown AJ. 2005. Acute regulation of parathyroid hormone by dietary phosphate. Am. J. Physiol. Endocrinol. Metab. 289:E729-34
36. Brown AJ, Koch MJ, Coyne DW. 2006. Oral feeding acutely down-regulates serum PTH in hemodialysis patients. Nephron. Clin. Pract. 103:c106-13
37. Lorenz JN, Nieman M, Sabo J, Sanford LP, Hawkins JA, et al. 2003. Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enteral NaCl load. J. Clin. Invest. 112:1244-54
38. Fan X, Wang Y, London RM, Eber SL, Krause WJ, et al. 1997. Signaling pathways for guanylin and uroguanylin in the digestive, renal, central nervous, reproductive, and lymphoid systems. Endocrinology 138:4636-48
39. Potthast R, Ehler E, Scheving LA, Sindic A, Schlatter E, Kuhn M. 2001. High salt intake increases uroguanylin expression in mouse kidney. Endocrinology 142:3087-97
40. Landsman A, Lichtstein D, Ilani A. 2005. Distinctive features of dietary phosphate supply. J. Appl. Physiol. 99:1214-19
41. Landsman A, Lichtstein D, Bacaner M, Ilani A. 2001. Dietary phosphate-dependent growth is not mediated by changes in plasma phosphate concentration. Br. J. Nutr. 86:217-23
42. Rybczynska A, Hoppe A, Knox FG. 1990. Propranolol restores phosphaturic effect of PTH in short-term phosphate deprivation. Am. J. Physiol. 258:R120-23
43. Beck N, Webster SK, Reineck HJ. 1979. Effect of fasting on tubular phosphorus reabsorption. Am. J. Physiol. 237:F241-46
44. Kempson SA, Shah SV, Werness PG, Berndt T, Lee PH, et al. 1980. Renal brush border membrane adaptation to phosphorus deprivation: effects of fasting versus low-phosphorus diet. Kidney Int. 18:36-47
45. Markovich D, Verri T, Sorribas V, Forgo J, Biber J, Murer H. 1995. Regulation of opossum kidney (OK) cell Na/Pi cotransport by Pi deprivation involves mRNA stability. Pflügers Arch. 430:459-63
46. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, et al. 1994. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N. Engl. J. Med. 330:1645-49
47. Econs MJ, Drezner MK. 1994. Tumor-induced osteomalacia - unveiling a new hormone. N. Engl. J. Med. 330:1679-81
48. Kumar R. 1997. Phosphatonin - a new phosphaturetic hormone? (lessons from tumor-induced osteomalacia and X-linked hypophosphataemia). Nephrol. Dial. Transplant. 12:11-13
49. Kumar R. 2000. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 27:333-38
50. Drezner MK. 2003. Hypophosphatemic rickets. Endocr. Dev. 6:126-55
51. Drezner MK. 2000. PHEX gene and hypophosphatemia. Kidney Int. 57:9-18
52. Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, et al. 1995. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat. Genet. 11:130-36
53. ADHR Consortium. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26:345-48
54. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, et al. 2000. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68
55. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, et al. 2004. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-19
56. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, et al. 2003. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112:785-94
57. De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, et al. 2002. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J. Bone Miner. Res. 17:1102-10
58. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. 2005. FGF7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 90:1012-20
59. Deleted in proof
60. Schiavi SC, Kumar R. 2004. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 65:1-14
61. Schiavi SC, Moe OW. 2002. Phosphatonins: a new class of phosphate-regulating proteins. Curr. Opin. Nephrol. Hypertens. 11:423-30
62. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, et al. 2002. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-82
63. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. 2001. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60:2079-86
64. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98:6500-5
65. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, et al. 2001. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem. Biophys. Res. Commun. 284:977-81
66. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, et al. 2004. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 89:3979-82
67. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. 2002. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87:4957-60
68. Larsson T, Zahradnik R, Lavigne J, Ljunggren O, Juppner H, Jonsson KB. 2003. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur. J. Endocrinol. 148:269-76
69. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, et al. 2003. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348:1656-63
70. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, et al. 2004. Transgenic mice expressing fibroblast growth factor 23 under the control of the alphal(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-94
71. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, et al. 2004. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314:409-14
72. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, et al. 2004. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113:561-68
73. Meyer RAJ, Tenenhouse HS, Meyer MH, Klugerman AH. 1989. The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J. Bone Miner. Res. 4:523-32
74. Meyer RAJ, Meyer MH, Gray RW. 1989. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J. Bone Miner. Res. 4:493-500
75. Nesbitt T, Coffman TM, Griffiths R, Drezner MK. 1992. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J. Clin. Invest. 89:1453-59
76. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, et al. 2003. Human recombinant endopeptidase PHEX has a strict S1′ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem. J. 373:271-79
77. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. 2006. Pathogenic role of FGF23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 298:E38-49
78. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. 2003. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64:2272-79
79. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, et al. 2004. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 36:579-81
80. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, et al. 2005. A novel mutation in fibroblast growth factor (FGF)23 gene as a cause of tumoral calcinosis. J. Clin. Endocrinol. Metab. 90:5523-37
81. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, et al. 2005. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146:3883-91
82. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. 2005. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14:385-90
83. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, et al. 2005. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J. Clin. Endocrinol. Metab. 90:2424-27
84. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N. 2002. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J. Biol. Chem. 277:28265-70
85. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, et al. 2005. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146:4647-56
86. i cotransporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells 10:489-502
87. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, et al. 2006. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281:6120-23
88. Baum M, Schiavi S, Dwarakanath V, Quigley R. 2005. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 68:1148-53
89. Ferrari SL, Bonjour JP, Rizzoli R. 2005. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90:1519-24
90. Nishida Y, Yamanaka-Okumura H, Taketani Y, Sato T, Nashiki K, et al. 2005. Postprandial changes of serum fibroblast growth factor 23 (FGF23) levels on high phosphate diet in healthy men. Presented at Annu. Meet. ASBMR, 27th, Nashville
91. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. 2005. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358-64
92. Sommer S, Berndt T, Craig TA, Kumar R. 2006. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J. Steroid Biochem. Mol. Biol. In press
93. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, et al. 2005. Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280:2543-49
94. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, et al. 2005. 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 289:G1036-42
95. Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, et al. 2005. Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D. J. Bone Miner. Res. 20:1944-50
96. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, et al. 2006. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17:1305-15
97. Nusse R. 2005. Cell biology: relays at the membrane. Nature 438:747-49
98. Nusse R. 2005. Wnt signaling in disease and in development. Cell Res. 15:28-32
99. Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20:781-810
100. Nusse R. 2003. Wilts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 130:5297-305
101. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, et al. 2003. Tirgeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J. Biol. Chem. 278:1998-2007
102. Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, et al. 2005. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36:33-46
103. Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS. 2004. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J. Endocrinol. 183:R1-9
104. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, et al. 2004. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J. Clin. Endocrinol. Metab. 89:4158-61
105. Berndt TJ, Bielesz B, Craig TA, Tebben PJ, Bacic D, et al. 2006. Secreted frizzled related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflügers Arch. 451(4):579-87